Dr. Ali El-Ghamrawy, Chairman of the Egyptian Drug Authority (EDA), held a meeting with representatives from the global pharmaceutical company Abbott to discuss the latest developments regarding the localization of certain Abbott products in Egypt.
The meeting aimed to address key issues affecting the pharmaceutical sector in Egypt and foster a strategy of exchanging ideas and perspectives to enhance partnership and cooperation in support of national pharmaceutical industry goals.
Dr. El-Ghamrawy emphasized the importance of advancing the localization plan for Abbott’s products in the Egyptian pharmaceutical market to ensure local production begins as soon as possible. He also reiterated the EDA’s commitment to supporting domestic pharmaceutical manufacturing by promptly addressing any challenges that may hinder localization efforts.
The Chairman highlighted the strong and constructive collaboration between the EDA and Abbott, stressing the importance of ongoing and effective communication and coordination to achieve the localization of various medical products in Egypt.
During the meeting, the parties discussed the localization strategy for selected Abbott pharmaceutical products in Egypt, the registration of biological products, and the EDA’s vision for 2025. They also explored potential avenues for future cooperation aimed at supporting Egypt’s efforts to achieve self-sufficiency in medicine and keep pace with global advancements in this vital sector.
At the conclusion of the meeting, both sides reaffirmed the importance of continued coordination and overcoming any obstacles that may arise in implementing plans and initiatives. They also underscored the strength of the relationship between the EDA and Abbott, and the vital role such partnerships play in achieving sustainable development and enhancing national pharmaceutical manufacturing capabilities.
Participants from the EDA included Dr. Amany Gawdat, Associate to the EDA Chairman and Supervisor of the Central Administration for the Chairman’s Office,Dr. Asmaa Fouad, Head of the Central Administration for Biological, Innovative Products and Clinical Studies and Dr. Osama Hatem, Associate to the EDA Chairman for Policy and International Cooperation and Supervisor of the Administration for Pharmaceutical Policy and Market Access.
Representing Abbott were Dr. Sami Karam, Vice President for Emerging Markets, Dr. Asim Cifter, Vice President for the Middle East, Turkey, Africa, and CIS region, Dr. Barbaros Durgun, Regional Market Access Director for the Middle East, Turkey, Africa, and CIS region, Dr. Mohamed Kandil, Regional Director for Egypt, Saudi Arabia, and Africa, Dr. Hany Hanser, Government Affairs Director for the Middle East and Dr. Amr Yehia, General Manager of Abbott Egypt.
This initiative reflects the EDA’s ongoing commitment to strengthening communication with industry partners, advancing the localization of priority medicines for Egyptian citizens in line with national plans, attracting more investment, and expanding Egypt’s pharmaceutical market—especially in neighboring and African markets.

"